RxDoctor Payments Data

Andrew Dewolfe, MD

Cardiovascular Disease · Safety Harbor, FLNPI 1235372368

Payments from drug & device makers

$158,043in general payments, 2019–2025

Across 154 payments — averaging $1026.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$95K
  • Novartis$42K
  • AstraZeneca$19K
  • Amgen$980
  • E.r. Squibb & Sons, L.L.C.$346
  • W. L. Gore & Associates, Inc.$146
  • plus $712 from 12 others
$7,530in research payments, 2019–2025

Across 2 payments — averaging $3764.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$8K

What the payments were for

  • Food & beverage$2,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,043 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$356,161
Medicare patients
1,438
Services billed
3,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban352$402,406
VyndamaxTafamidis13$289,690
XareltoRivaroxaban143$159,717
Repatha SureclickEvolocumab83$77,775
FarxigaDapagliflozin Propanediol42$32,221
BrilintaTicagrelor34$31,672
Praluent PenAlirocumab25$21,959
EntrestoSacubitril/Valsartan19$14,493
OzempicSemaglutide12$12,580
EdarbyclorAzilsartan Med/Chlorthalidone17$10,209
Metoprolol Succinate384$4,892
Flecainide Acetate100$4,240
Valsartan152$3,784
EdarbiAzilsartan Medoxomil13$3,571
Amiodarone Hcl80$3,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$112$692,096365 claims
Johnson & JohnsonXarelto$140$159,717143 claims
AstraZenecaFarxiga, Brilinta$18,946$63,89276 claims
NovartisEntresto$42,377$14,49319 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$46$13,78030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Safety Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →